Showing posts with label FDA Warning Letters. Show all posts
Showing posts with label FDA Warning Letters. Show all posts

Saturday, May 3, 2008

U.S. Food & Drug Administration (FDA) Daily Digest Bulletin

Update: 1

From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 07:41:34 -0500 (CDT)
Subject: CDRH New Update

Skip NavigationFDA Logo links to FDA home pageCenter for Devices and Radiological Health, U.S. Food and Drug AdministrationHHS Logo links to Department of Health and Human Services website

FDA Home Page | CDRH Home Page | Search | A-Z Index U.S. Food and Drug AdministrationCenter for Devices and Radiological Health Questions?
horizonal rule
CDRHNEW Logo Date: May 1, 2008

The following new items were added to the CDRH web pages on April 30, 2008. Previous CDRH New Items can be found on the CDRHNew Page.

* Federal Register: Towards an Artificial Pancreas: A Food and Drug Administration, National Institutes of Health, Juvenile Diabetes Research Foundation Public Workshop. Text PDF
* Federal Register: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Additional Listing Information for Medical Device Registration and Listing. Text PDF

---


Update: 2
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 08:42:00 -0500 (CDT)
Subject: CDER New 4/30/2008

FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

CDERnew Logo

April 30, 2008


Update: 3
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 09:03:49 -0500 (CDT)
Subject: FDA Completes Final Analysis of "Total Body Formula" and "Total Body Mega Formula" Products

FDA Completes Final Analysis of "Total Body Formula" and "Total Body Mega Formula" Products
Thu, 1 May 2008 08:02:00 -0500

The U.S. Food and Drug Administration's final analysis of certain flavors of "Total Body Formula" and "Total Body Mega Formula" has detected hazardous amounts of chromium.


Update: 4
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 09:04:15 -0500 (CDT)
Subject: Enforcement Report for April 30, 2008

Enforcement Report for April 30, 2008
Thu, 1 May 2008 08:38:00 -0500

Weekly report by the Food and Drug Administration, Department of Health and Human Services. It contains information on actions taken in connection with agency Regulatory activities.


Update: 5
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 14:06:52 -0500 (CDT)
Subject: U.S. Food & Drug Administration (FDA) CBER's Recalls, Withdrawals, Field Corrections & Notifications Update

You are subscribed to CBER's Recalls, Withdrawals, Field Corrections & Notifications for U.S. Food & Drug Administration (FDA). This information has recently been updated, and is now available.

Withdrawal of Albumin (Human) 5%, Talecris Biotherapeutics
Posted: 5/1/2008; Withdrawal Date: 4/30/2008


Update: 6
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 15:22:16 -0500 (CDT)
Subject: Interstate Certified Shellfish Shippers Update May 2008

* * * Interstate Certified Shellfish Shippers List * * *

The monthly ICSSL update is now available for download at http://www.cfsan.fda.gov/~ear/shellfis.html.

May 2008 Update


Update: 7
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 16:04:52 -0500 (CDT)
Subject: Drug Approved for Irritable Bowel Syndrome with Constipation

Drug Approved for Irritable Bowel Syndrome with Constipation
Thu, 1 May 2008 13:04:00 -0500

FDA has approved Amitza (lubiprostone) for the treatment of irritable bowel syndrome with constipation in adult women aged 18 and over


Update: 8
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 16:05:03 -0500 (CDT)
Subject: Device Identifies Fatty Deposits in Coronary Arteries

Device Identifies Fatty Deposits in Coronary Arteries
Thu, 1 May 2008 13:04:00 -0500

A new medical device allows doctors to see the plaque buildup on the wall of coronary arteries. Many heart attacks occur when a fatty coronary plaque ruptures, forming dangerous blood clots.


Update: 9
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 16:05:09 -0500 (CDT)
Subject: Combating Antibiotic Resistance

Combating Antibiotic Resistance
Thu, 1 May 2008 13:04:00 -0500

Misuse and overuse of antibiotics have contributed to antibiotic resistance, a phenomenon that reduces or eliminates the effectiveness of antibiotics.


Update: 10
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 16:13:47 -0500 (CDT)
Subject: FDA Data Standards Update - SPL Terminology Update - Marketing Categories

Greetings,

The FDA Data Standards Council's SPL web page was updated Thursday, May 1, 2008, to add terms and codes for marketing categories.

The new terms and codes are located on this web page: http://www.fda.gov/oc/datacouncil/term.html#marcat.

.

Lonnie Smith

Project Manager

Food and Drug Administration


Update: 11
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 2 May 2008 07:48:02 -0500 (CDT)
Subject: CDER New 5/1/2008

FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

CDERnew Logo

May 1, 2008


Update: 12
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 2 May 2008 09:03:28 -0500 (CDT)
Subject: Drug to be Discontinued: Tilade Inhaler (nedocromil sodium inhalation aerosol)

FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

Drug to be Discontinued: Tilade Inhaler (nedocromil sodium inhalation aerosol)
Fri, 2 May 2008 09:45:00 -0500

Dear Healthcare Professional Letter is available.


Update: 13
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 2 May 2008 16:18:07 -0500 (CDT)
Subject: FDA Data Standards Update - UNII Update

The FDA Data Standards Council's website was updated Friday, May 2, 2008, to include an update to the list of Unique Ingredient Identifiers (UNIIs).

Hyperlinks to the updated list of UNIIs can be found on either of these web pages:

Substance Registration System - Unique Ingredient Identifier: http://www.fda.gov/oc/datacouncil/SRS.htm

Structured Product Labeling Resources: http://www.fda.gov/oc/datacouncil/spl.html

Lonnie Smith

Project Manager

Food and Drug Administration


Update: 14
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 2 May 2008 17:03:56 -0500 (CDT)
Subject: Little Bay Baking Company Issues Nationwide Allergy Alert On Undeclared Soy In Corn Bread And Muffin Mix in 12.6 Ounce White Paper Tin Tie Bag Package (May 2)

Little Bay Baking Company Issues Nationwide Allergy Alert On Undeclared Soy In Corn Bread And Muffin Mix in 12.6 Ounce White Paper Tin Tie Bag Package (May 2)
Fri, 2 May 2008 16:33:00 -0500

Little Bay Baking Company of Newmarket, New Hampshire is recalling all bags of CORN BREAD AND MUFFIN MIX sold before May 2, 2008 because it contains undeclared soy. People who have an allergy or severe sensitivity to soy run the risk of serious or life-threatening allergic reaction if they consume these products.


Update: 15
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 1 May 2008 14:16:26 -0500 (CDT)
Subject: FDA MedWatch- Enbrel (etanercept)-Prescribing Information Revised To Include A Boxed Warning Regarding The Risk Of Infection, Including Tuberculosis

MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program

Amgen and Wyeth Pharmaceuticals informed healthcare professionals of revisions to prescribing information for Enbrel. The revisions include a BOXED WARNING about infections, including serious infections leading to hospitalization or death that have been observed in patients treated with Enbrel. Infections have included bacterial sepsis and tuberculosis. The ADVERSE REACTIONS section of the label was updated to include information regarding global clinical studies and the rate of occurrence of tuberculosis in patients treated with Enbrel. Healthcare professionals should screen patients for latent tuberculosis infection before beginning Enbrel. Patients should be educated about the symptoms of infection and closely monitored for signs and symptoms of infection during and after treatment with the drug. Patients who develop an infection should be evaluated for appropriate antimicrobial treatment and, in patients who develop a serious infection, Enbrel should be discontinued.

Read the entire 2008 MedWatch Safety Summary, including a link to the manufacturer's Dear Healthcare Professional Letter regarding this issue at: http://www.fda.gov/medwatch/safety/2008/safety08.htm#Enbrel


This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420

Wednesday, April 30, 2008

U.S. Food & Drug Administration (FDA) Daily Digest Bulletin

Update: 1
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 29 Apr 2008 05:46:14 -0500 (CDT)
Subject: CDRH New Update

Skip NavigationFDA Logo links to FDA home pageCenter for Devices and Radiological Health, U.S. Food and Drug AdministrationHHS Logo links to Department of Health and Human Services website

FDA Home Page | CDRH Home Page | Search | A-Z Index U.S. Food and Drug AdministrationCenter for Devices and Radiological Health Questions?
horizonal rule
CDRHNEW Logo Date: April 29, 2008

The following new items were added to the CDRH web pages on April 28, 2008. Previous CDRH New Items can be found on the CDRHNew Page.

* Federal Register: Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Reopening of Comment Period. Text PDF

---


Update: 2
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 29 Apr 2008 07:08:21 -0500 (CDT)
Subject: U.S. Food & Drug Administration (FDA) CBER's Proposed and Final Rules Update

You are subscribed to CBER's Proposed and Final Rules for U.S. Food & Drug Administration (FDA). This information has recently been updated, and is now available.

FEDERAL REGISTER: Human Subject Protection; Foreign Clinical Studies Not Conducted Under an Investigational New Drug Application; Final Rule - 4/29/2008


Update: 3
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 29 Apr 2008 07:35:09 -0500 (CDT)
Subject: Good Clinical Practice Update (April 29, 2008)

You are a subscriber to the Good Clinical Practice/ Human Subject Protection e-mail update service provided by the U.S. Food & Drug Administration (FDA). The following information was recently added to our home page under the "In the News" section:

--> The Federal Register publication on foreign clinical studies not conducted under an investigational new drug application (21 CFR 312.120) <---

You can find this information at www.fda.gov/oc/gcp .


Update: 4
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 29 Apr 2008 08:05:11 -0500 (CDT)
Subject: Coronary Artery Plaque Imaging Device Cleared by FDA

Coronary Artery Plaque Imaging Device Cleared by FDA
Tue, 29 Apr 2008 07:42:00 -0500

The U.S. Food and Drug Administration has cleared for marketing a device that a doctor can use to see inside a blood vessel to assess the fat content of the plaque which builds up on the wall of the coronary arteries.


Update: 5
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 29 Apr 2008 09:32:41 -0500 (CDT)
Subject: FDA Data Standards Update - SPL Terminology Update: Business Operations

Greetings,

The FDA Data Standards Council's SPL web page was updated yesterday, Monday, April 28, 2008, to replace the term and code for "importer" and add these new terms and codes:

IMPORT C73599

RELABEL C73607

REPACK C73606

The new terms and codes are located on this web page: http://www.fda.gov/oc/datacouncil/term.html#busop

.

Lonnie Smith

Project Manager

Food and Drug Administration


Update: 6
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 29 Apr 2008 18:04:32 -0500 (CDT)
Subject: FDA Approves Amitiza for IBS-C

FDA Approves Amitiza for IBS-C
Tue, 29 Apr 2008 17:45:00 -0500

The U.S. Food and Drug Administration has approved Amitiza (lubiprostone) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women aged 18 and over.


This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420